MONROVIA, Calif.--(BUSINESS WIRE)--Jan 4, 2023--

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on January 11, 2023 at 3:45 p.m. PST.

A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of the Company’s website. A replay will be available for at least 30 days following the presentation.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor’s XmAb ® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor’s XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230104005829/en/

CONTACT: Charles Liles

cliles@xencor.com

626-737-8118

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY INFECTIOUS DISEASES HEALTH PHARMACEUTICAL ONCOLOGY

SOURCE: Xencor, Inc.

Copyright Business Wire 2023.

PUB: 01/04/2023 04:01 PM/DISC: 01/04/2023 04:00 PM

http://www.businesswire.com/news/home/20230104005829/en